>
Swap Lines: The Federal Reserve Extends Its Tightrope
The Transgender Mirage Is Cracking
The Collapse of the Saudi-American Alliance?
BREAKING: EPA eliminates rule that limits 'greenhouse gas' emissions from power plants
Quantum computing may soon become part of the microscope itself.
Volkswagen Just Unveiled The Most Efficient EV Ever Tested
NASA Super Light Solar Sail Project Will Be 12-40 Times Lighter and Faster
Space Telescope Interferometer to Image Exoplanet Continents
Twenty-five years of "temporary": how 9/11 built a surveillance state Americans never vote
I'll Never Buy Another WALMART Battery!
Shoei GT-Air 3 Smart helmet drops with built-in AR for $1,500
AI Whistleblower Tells Tucker How AI Could Kill All Humans by 2040

The small, randomized, placebo-controlled trial found the treatment both safe and effective, with larger trials hoped to validate the results in more diverse populations.
The most common form of age-related baldness is known as androgenetic alopecia (AGA). Around half of men and women over the age of 50 will deal with some form of this hair loss, from a receding hairline to more general hair thinning.
The new trial focused on a type of stem cell abundantly found in adult fat tissue, called adipose tissue?derived stem cells (ADSCs), which have been found to secrete a number of growth hormones vital to hair development. Smaller studies have demonstrated ADSCs can regrow hair in male and female subjects but this is the first robust human clinical trial to test a novel topical treatment against a placebo.
"Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia," explains Sang Yeoup Lee, from Pusan National University in South Korea. "However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent."